AstraZeneca: Hemorrhage trials
The registry lists 12 Hemorrhage studies with AstraZeneca as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 1Phase 2 3Phase 3 4No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban DosingTerminatedNCT03330457Phase 2Results posted
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian SubjectsCompletedNCT03310021Phase 2Results posted
- A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)CompletedNCT02329327Phase 3Results posted
- A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of RivaroxabanCompletedNCT02220725Phase 3Results posted
- A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of ApixabanCompletedNCT02207725Phase 3Results posted
- A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)WithdrawnNCT06575517
- Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With OndexxyaCompletedNCT05898412
- Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical PracticeCompletedNCT04568083
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet AlfaCompletedNCT03083704Phase 1
- European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)CompletedNCT00797641
- Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a StrokeCompletedNCT00075959Phase 2
- Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a StrokeCompletedNCT00061022Phase 3